BROOMFIELD, Colo., May 17, 2022 / — Alio™, a medical technology company reinventing the management of chronic disease and bringing peace of mind to people on dialysis, announced today David Kuraguntla, Chief Executive Officer, Rajesh Sivaprakasam, MD, FRCS, and Bart Dolmatch, MD, will be presenting in upcoming clinical-scientific conferences.
EuroPCR Meeting
May 17-20. 2022
Paris, France
Presentation: Innovators Day, Dave Kuraguntla, CEO, Alio, Thursday, 19 May 2022
https://www.pcronline.com/Courses/EuroPCR
Vascular Access for Hemodialysis Symposium / Vascular Access Society of the Americas / VASA 2022
June 9-11, 2022
Charleston, SC
Presentations: Innovation Session, Dave Kuraguntla, CEO, Alio, Thursday, 9 June 2022
Podium Presentation Wearables, Rajesh Sivaprakasam, MD, FRCS, Saturday, 11 June 2022
https://www.vasamd.org/events/2022-sponsor-exhibitor-opportunities
EVC – 25th European Vascular Course
June 12-14, 2022
Maastricht, The Netherlands
Presentation: Wearables. Next Level of Surveillance? Bart Dolmatch, MD, Saturday, 25 June 2022
https://esvs.org/event/evc_2022/
About Alio
Alio, Inc. (Broomfield, CO), is a medical technology company developing SmartPatch™ technology and using artificial intelligence (AI) to monitor multiple chronic indications, including end stage kidney disease (ESKD) patients undergoing hemodialysis. Alio is dedicated to the development of remote monitoring that provides actionable clinical data for a variety of conditions to better target interventions for improved outcomes and reduced hospitalizations.